Complications in Anesthesia Practice Questions

Q: A 45-year-old patient undergoing surgery develops tachycardia and hyperthermia intraoperatively. Which agent should be avoided in future anesthetics for this patient?

Desflurane. ***Desflurane*** - The development of intraoperative **tachycardia** and **hyperthermia** is highly suggestive of **malignant hyperthermia (MH)**, a genetic disorder triggered by volatile anesthetic agents and succinylcholine. - **Desflurane** is a volatile anesthetic and a known trigger for MH, thus it should be avoided in future anesthetics for this patient. *Thiopental* - **Thiopental** is a short-acting barbiturate used for induction of anesthesia, and it is **not a trigger for malignant hyperthermia**. - It would be considered a safe alternative for future anesthetics in a patient susceptible to MH. *Fentanyl* - **Fentanyl** is an opioid analgesic commonly used during anesthesia; it is **not a triggering agent for malignant hyperthermia**. - Opioids are generally safe to use in patients with a history of MH. *Etomidate* - **Etomidate** is an intravenous anesthetic agent primarily used for induction, and it is **not associated with malignant hyperthermia**. - It presents a safe option for induction in patients with a history of MH.

Q: What is the most likely cause of a sudden increase in end-tidal CO2 in a patient undergoing general anesthesia?

Malignant hyperthermia. ***Malignant hyperthermia*** - This condition is characterized by a rapid and severe increase in **metabolic rate**, leading to excessive CO2 production. - A sudden and unexplained rise in **end-tidal CO2** is often the earliest and most sensitive sign during anesthesia. *Hypothermia* - **Hypothermia** generally decreases metabolic rate, leading to a *decrease* in CO2 production and end-tidal CO2, not an increase. - Reduced body temperature slows enzymatic reactions and cellular activity. *Hypoventilation* - While **hypoventilation** leads to an *increase* in end-tidal CO2, it typically occurs due to inadequate ventilation settings or respiratory depression, which would be addressed by increasing ventilation. - A sudden and dramatic increase in end-tidal CO2 in the setting of adequate ventilation often points to increased CO2 production rather than just impaired elimination. *Low cardiac output* - **Low cardiac output** can lead to decreased CO2 delivery to the lungs, resulting in a *decrease* in end-tidal CO2 due to reduced pulmonary blood flow. - This results in a larger difference between arterial and end-tidal CO2, not an increase in end-tidal CO2.

Q: In a patient undergoing laparoscopic cholecystectomy, sudden bradycardia and hypotension occur. What is the most likely cause?

Vagal stimulation. ***Vagal stimulation*** - **Peritoneal distension** due to pneumoperitoneum can lead to vagal stimulation, causing **bradycardia** and **hypotension** during laparoscopic cholecystectomy. - Manipulation of the **gallbladder** or surrounding structures can also directly stimulate the vagus nerve. *Gas embolism* - A gas embolism is a less common but serious complication, typically presenting with **sudden desaturation**, **hypotension**, and a **"mill-wheel" murmur**. - While it can cause hypotension, bradycardia is not its hallmark; rather, it often leads to **tachycardia** as the heart attempts to compensate. *Hypovolemia* - Hypovolemia would primarily cause **tachycardia** and hypotension as the body tries to maintain cardiac output. - Bradycardia would be an unusual initial presentation associated with hypovolemia unless it's a profound, pre-terminal event. *Myocardial infarction* - Although possible during any surgical procedure, a myocardial infarction typically presents with **ECG changes** (e.g., ST-segment elevation), **chest pain** (though sometimes masked by anesthesia), and potentially **tachycardia** or other arrhythmias, not typically isolated bradycardia. - While some inferior wall MIs can cause bradycardia due to vagal tone, the combination with sudden hypotension in the context of laparoscopic surgery makes vagal stimulation a more direct and common cause.

Q: Which of the following is the most reliable sign of malignant hyperthermia?

Hypercarbia. ***Hypercarbia*** - **Hypercarbia** (elevated end-tidal CO2) is often the earliest and most consistent sign of malignant hyperthermia, reflecting increased cellular metabolism and CO2 production. - This symptom precedes other clinical signs because the body's compensatory mechanisms for CO2 excretion are overwhelmed quickly. *Tachycardia* - **Tachycardia** is a common sign of stress and can be caused by many factors during surgery, making it a non-specific indicator of malignant hyperthermia. - While it is typically present in malignant hyperthermia, it usually appears after hypercarbia has already developed. *Muscle rigidity* - **Muscle rigidity**, particularly masseter spasm, is a characteristic but not universally present or earliest sign of malignant hyperthermia. - It results from uncontrolled calcium release in muscle cells, but its onset can be delayed, and it may not be apparent in all muscle groups. *Hyperthermia* - **Hyperthermia** is a defining feature of malignant hyperthermia, but it is often a late sign, as the body's temperature regulation mechanisms are overwhelmed. - Measuring core body temperature can be slow, and a significant rise in temperature might occur after other signs like hypercarbia have been present for some time.

Q: What is the first-line treatment for malignant hyperthermia?

Dantrolene. ***Dantrolene*** - **Dantrolene** is a direct-acting **skeletal muscle relaxant** that works by inhibiting calcium release from the sarcoplasmic reticulum. - This directly addresses the underlying pathophysiology of malignant hyperthermia, which involves excessive intracellular calcium and muscle contraction. *Supportive cooling measures* - While important for managing the **hyperthermia** component, cooling measures alone do not address the fundamental mechanism of excessive calcium release. - They are a crucial adjunct to dantrolene, but not the primary or definitive treatment. *Hydration with intravenous fluids* - **Intravenous fluids** help maintain **hemodynamic stability** and prevent **renal damage** due to rhabdomyolysis, a common complication of malignant hyperthermia. - However, they do not target the excessive calcium release responsible for the muscle rigidity and metabolic crisis. *Use of vasopressors* - **Vasopressors** may be used to manage hypothetical **hypotension** cases occurring in patients, but not as a primary treatment. - These drugs do not tackle the underlying **pathophysiology** of malignant hyperthermia, and their use is purely symptomatic and supportive.

Q: Which of the following is a known trigger for malignant hyperthermia?

Halothane. ***Halothane*** - **Halothane** is a potent volatile anesthetic and a classic trigger for malignant hyperthermia. - It induces a rapid, uncontrolled rise in intracellular calcium in skeletal muscle cells, leading to a hypermetabolic state. *Propofol* - **Propofol** is an intravenous anesthetic and is considered a safe anesthetic agent for patients susceptible to malignant hyperthermia. - It does not interact with the **ryanodine receptor (RyR1)**, which is central to the pathophysiology of malignant hyperthermia. *Thiopental* - **Thiopental** is a short-acting barbiturate and an intravenous anesthetic also considered safe for patients with a risk of malignant hyperthermia. - Its mechanism of action does not involve the biochemical pathways implicated in this genetic disorder. *Ketamine* - **Ketamine** is a dissociative anesthetic and is another agent that does not trigger malignant hyperthermia. - It is often used as an alternative anesthetic in patients with known or suspected malignant hyperthermia susceptibility.

Q: During general anesthesia, if a patient develops tachycardia, hyperthermia, and muscle rigidity, what is the initial treatment?

Administer dantrolene. ***Administer dantrolene*** - The combination of **tachycardia**, **hyperthermia**, and **muscle rigidity** during general anesthesia is highly indicative of **malignant hyperthermia (MH)**, a life-threatening pharmacogenetic disorder. - **Dantrolene** is the specific and most effective antidote for MH, acting by inhibiting calcium release from the sarcoplasmic reticulum in muscle cells, thereby reducing muscle rigidity and heat production. *Administer supportive intravenous fluids* - While **intravenous fluids** are crucial for maintaining hydration and supporting cardiovascular function during MH, they are **supportive measures** and not the primary, specific treatment. - Fluids alone will not address the underlying pathophysiology of excessive calcium release and hypermetabolism in muscle cells. *Implement cooling measures* - **Cooling measures** (e.g., ice packs, cold IV fluids, gastric lavage) are essential to combat the severe **hyperthermia** seen in MH, which can lead to organ damage. - However, cooling is a **symptomatic treatment** and must be initiated *in conjunction with* dantrolene, as it does not address the root cause of the metabolic crisis. *Administer a muscle relaxant* - Administering a **general muscle relaxant** without dantrolene is generally ineffective in MH because traditional muscle relaxants like rocuronium or vecuronium act at the neuromuscular junction, whereas the rigidity in MH is due to **intracellular calcium dysregulation** within the muscle fiber itself. - In fact, depolarizing muscle relaxants like succinylcholine can trigger MH in susceptible individuals, and non-depolarizing agents would not effectively reverse the sustained muscle contraction of an MH crisis.

Q: Which medication is contraindicated in a patient with a history of malignant hyperthermia?

Sevoflurane. ***Sevoflurane*** - **Sevoflurane** is an **inhaled volatile anesthetic** known to be a potent trigger for **malignant hyperthermia (MH)** due to its ability to induce uncontrolled calcium release from the sarcoplasmic reticulum in susceptible individuals. - Patients with a history of MH, or those genetically predisposed to it, should strictly avoid sevoflurane and other volatile anesthetics (e.g., halothane, isoflurane, desflurane) to prevent a life-threatening hypermetabolic crisis. *Propofol* - **Propofol** is an **intravenous anesthetic** and is considered a **safe anesthetic agent** in patients with a history of malignant hyperthermia. - It does not trigger the unregulated calcium release in muscle cells that characterizes malignant hyperthermia. *Rocuronium* - **Rocuronium** is a **nondepolarizing neuromuscular blocking agent** and is **safe for use** in patients susceptible to malignant hyperthermia. - It works by competing with acetylcholine at the neuromuscular junction without directly affecting calcium regulation within muscle cells. *Etomidate* - **Etomidate** is an **intravenous hypnotic agent** commonly used for induction of anesthesia, and it is **not a known trigger for malignant hyperthermia**. - Its mechanism of action involves enhancing GABAergic transmission, which does not interfere with the calcium channels implicated in MH.

Question 1

A 45-year-old patient undergoing surgery develops tachycardia and hyperthermia intraoperatively. Which agent should be avoided in future anesthetics for this patient?

Accepted Answer

Desflurane

Answer

Thiopental

Answer

Fentanyl

Answer

Etomidate

Question 2

What is the most likely cause of a sudden increase in end-tidal CO2 in a patient undergoing general anesthesia?

Accepted Answer

Malignant hyperthermia

Answer

Hypothermia

Answer

Hypoventilation

Answer

Low cardiac output

Question 3

In a patient undergoing laparoscopic cholecystectomy, sudden bradycardia and hypotension occur. What is the most likely cause?

Accepted Answer

Vagal stimulation

Answer

Gas embolism

Answer

Hypovolemia

Answer

Myocardial infarction

Question 4

A patient undergoing surgery exhibits a sudden drop in oxygen saturation, a decrease in blood pressure, and increased peak airway pressures. Analyze the scenario and determine the likely diagnosis and the immediate action required.

Accepted Answer

Tension pneumothorax; perform needle decompression immediately

Answer

Pulmonary embolism; administer anticoagulants

Answer

Anaphylaxis; administer epinephrine immediately

Answer

Aspiration pneumonia; initiate broad-spectrum antibiotics

Question 5

Which of the following is the most reliable sign of malignant hyperthermia?

Accepted Answer

Hypercarbia

Answer

Tachycardia

Answer

Hyperthermia

Answer

Muscle rigidity

Question 6

What is the first-line treatment for malignant hyperthermia?

Accepted Answer

Dantrolene

Answer

Supportive cooling measures

Answer

Hydration with intravenous fluids

Answer

Use of vasopressors

Question 7

Which of the following is a known trigger for malignant hyperthermia?

Accepted Answer

Halothane

Answer

Propofol

Answer

Thiopental

Answer

Ketamine

Question 8

What is the most comprehensive approach to preventing perioperative hypothermia?

Accepted Answer

Prewarming the patient, using warm intravenous fluids, and maintaining room temperature

Answer

Using warm intravenous fluids

Answer

Maintaining room temperature

Answer

Prewarming the patient

Question 9

During general anesthesia, if a patient develops tachycardia, hyperthermia, and muscle rigidity, what is the initial treatment?

Accepted Answer

Administer dantrolene

Answer

Administer a muscle relaxant

Answer

Administer supportive intravenous fluids

Answer

Implement cooling measures

Question 10

Which medication is contraindicated in a patient with a history of malignant hyperthermia?

Accepted Answer

Sevoflurane

Answer

Propofol

Answer

Rocuronium

Answer

Etomidate

Complications in Anesthesia — MCQs

Complications in Anesthesia — MCQs

On this page

Practice by Chapter

Want unlimited practice?